UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 317

Sortiert nach

Temporal trends, clinical patterns and outcomes of NAFLD‐related HCC in patients undergoing liver resection over a 20‐year period

Alimentary Pharmacology & Therapeutics (Suppl), 2017-11, Vol.46 (9), p.856-863

2017

Volltextzugriff (PDF)

Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease

Alimentary pharmacology & therapeutics, 2014-11, Vol.40 (10), p.1209-1222

2014

Volltextzugriff (PDF)

Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology

Atherosclerosis, 2014-01, Vol.232 (1), p.99-109

2014

Volltextzugriff (PDF)

Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial

Nature Medicine, 2021-10, Vol.27 (10), p.1825-1835

2021

Volltextzugriff (PDF)

Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages

Clinical chemistry (Baltimore, Md.), 2007-09, Vol.53 (9), p.1615-1622

2007

Volltextzugriff (PDF)

Relationship between fatty liver, coronary calcium score, multiple-sites atherosclerosis and 10-years Framingham Score

Journal of hepatology, 2017, Vol.66 (1), p.S588-S589

2017

Volltextzugriff (PDF)

P327 PROFILING NEW BIOMARKERS FOR THE DIAGNOSIS OF DRUG INDUCED LIVER NECROSIS. A PILOT STUDY ASSESSING PERFORMANCE OF CLEAVED OR FULL-LENGTH CYTOKERATIN 18, AND MICRO-RNA-122

Journal of hepatology, 2014-04, Vol.60 (1), p.S175-S175

2014

Volltextzugriff (PDF)

Pharmacological agents for NASH

Nature reviews. Gastroenterology & hepatology, 2013-11, Vol.10 (11), p.676

Ratziu, Vlad

2013

Volltextzugriff (PDF)

Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease

Clinics and research in hepatology and gastroenterology, 2011-01, Vol.35 (1), p.23-28

2011

Volltextzugriff (PDF)

Impact of NASH, gender, fasting glucose and body mass index on the liver fibrosis transition rate (FTR) in metabolic liver disease (MLD)

Journal of hepatology, 2017, Vol.66 (1), p.S111-S111

2017

Volltextzugriff (PDF)

Serum Bile Acid Profiles are Associated with Histological Severity in Patients with Non-Alcoholic Fatty Liver Disease

Journal of hepatology, 2016, Vol.64 (2), p.S495-S495

2016

Volltextzugriff (PDF)

Regenerate: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Multicenter Study of Obeticholic Acid Therapy for Nonalcoholic Steatohepatitis

Journal of hepatology, 2016, Vol.64 (2), p.S294-S295

2016

Volltextzugriff (PDF)

Prediction of fibrosis improvement in patients with advanced fibrosis due to NASH using a machine learning approach: Unravelling the placebo response

Journal of hepatology, 2018, Vol.68, p.S97

2018

Volltextzugriff (PDF)

Histological progression of non‐alcoholic fatty liver disease: a critical reassessment based on liver sampling variability

Alimentary pharmacology & therapeutics, 2007-09, Vol.26 (6), p.821-830

2007

Volltextzugriff (PDF)

Prognostic value of liver fibrosis and steatosis biomarkers in type‐2 diabetes and dyslipidaemia

Alimentary pharmacology & therapeutics, 2014-11, Vol.40 (9), p.1081-1093

2014

Volltextzugriff (PDF)

345 A NEW METHODOLOGY FOR ASSESSING PROGRESSION OF LIVER FIBROSIS IN LARGE POPULATIONS USING VALIDATED BIOMARKER FIBROTEST® INSTEAD OF BIOPSY

Journal of hepatology, 2011-03, Vol.54, p.S138-S138

2011

Volltextzugriff (PDF)

Letter: FibroTest for staging fibrosis in non‐alcoholic fatty liver disease

Alimentary pharmacology & therapeutics, 2013-03, Vol.37 (6), p.655-656

2013

Volltextzugriff (PDF)

Combination drug therapy allows synergistic therapeutic dose reduction in NASH: a case study of elafibranor (GFT505) and an FXR agonist combination in a model of severe NASH

Journal of hepatology, 2017, Vol.66 (1), p.S113-S113

2017

Volltextzugriff (PDF)

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view

Gastroenterology (New York, N.Y. 1943), 1999-02, Vol.116 (2), p.378-386

1999

Volltextzugriff (PDF)

Advancing the global public health agenda for NAFLD: a consensus statement

Nature reviews. Gastroenterology & hepatology, 2022-01, Vol.19 (1), p.60

2022

Volltextzugriff (PDF)

Next-Generation Sequencing (NGS) of two independent cohorts identifies eleven circulating miRNAs for diagnosis of NASH and fibrosis

Journal of hepatology, 2017, Vol.66 (1), p.S110-S111

2017

Volltextzugriff (PDF)

Simple non-invasive fibrosis scores identify patients with non-alcoholic fatty liver disease who progress to advanced fibrosis/cirrhosis:evidence from a large cohort of patients with sequential liver biopsies

Journal of hepatology, 2017, Vol.66 (1), p.S68-S69

2017

Volltextzugriff (PDF)

Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies

Journal of hepatology, 2017, Vol.66 (1), p.S593-S593

2017

Volltextzugriff (PDF)

A new non-invasive diagnostic score to monitor change in disease activity and predict fibrosis evolution in patients with NASH

Journal of hepatology, 2017, Vol.66 (1), p.S110-S110

2017

Volltextzugriff (PDF)

Blood oxidative stress markers are unreliable markers of hepatic steatosis

Alimentary pharmacology & therapeutics, 2006-01, Vol.23 (1), p.91-98

2006

Volltextzugriff (PDF)

1 – 25 von 317

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(288)
Mit Volltextzugriff
(301)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Temporal trends, clinical patterns and outcomes of NAFLD‐related HCC in patients undergoing liver resection over a 20‐year period

Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease

Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology

Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial

Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages

Relationship between fatty liver, coronary calcium score, multiple-sites atherosclerosis and 10-years Framingham Score

P327 PROFILING NEW BIOMARKERS FOR THE DIAGNOSIS OF DRUG INDUCED LIVER NECROSIS. A PILOT STUDY ASSESSING PERFORMANCE OF CLEAVED OR FULL-LENGTH CYTOKERATIN 18, AND MICRO-RNA-122

Pharmacological agents for NASH

Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease

Impact of NASH, gender, fasting glucose and body mass index on the liver fibrosis transition rate (FTR) in metabolic liver disease (MLD)

Serum Bile Acid Profiles are Associated with Histological Severity in Patients with Non-Alcoholic Fatty Liver Disease

Regenerate: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Multicenter Study of Obeticholic Acid Therapy for Nonalcoholic Steatohepatitis

Prediction of fibrosis improvement in patients with advanced fibrosis due to NASH using a machine learning approach: Unravelling the placebo response

Histological progression of non‐alcoholic fatty liver disease: a critical reassessment based on liver sampling variability

Prognostic value of liver fibrosis and steatosis biomarkers in type‐2 diabetes and dyslipidaemia

345 A NEW METHODOLOGY FOR ASSESSING PROGRESSION OF LIVER FIBROSIS IN LARGE POPULATIONS USING VALIDATED BIOMARKER FIBROTEST® INSTEAD OF BIOPSY

Letter: FibroTest for staging fibrosis in non‐alcoholic fatty liver disease

Combination drug therapy allows synergistic therapeutic dose reduction in NASH: a case study of elafibranor (GFT505) and an FXR agonist combination in a model of severe NASH

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view

Advancing the global public health agenda for NAFLD: a consensus statement

Next-Generation Sequencing (NGS) of two independent cohorts identifies eleven circulating miRNAs for diagnosis of NASH and fibrosis

Simple non-invasive fibrosis scores identify patients with non-alcoholic fatty liver disease who progress to advanced fibrosis/cirrhosis:evidence from a large cohort of patients with sequential liver biopsies

Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies

A new non-invasive diagnostic score to monitor change in disease activity and predict fibrosis evolution in patients with NASH

Blood oxidative stress markers are unreliable markers of hepatic steatosis

Suchergebnisse filtern